Share

Studies soon opened

Studies opened since 01 January 2009

EORTC trial 08061
Phase II study of sunitinib (SU11248) in patients with small cell lung cancer who are either chemo-naïve (extensive disease) or have a “sensitive” relapse.

EORTC trial 22055-08053
Phase III study comparing post-operative conformal radiotherapy to no post-operative radiotherapy in patients with completely resected non-small cell lung cancer and mediastinal N2 involvement

Studies in regulatory process

EORTC trial 22043-30041
Post-operative external radiotherapy combined with concomitant and adjuvant hormonal treatment versus post-operative external radiotherapy alone in pathological stage pT3a-b R0-1/pT2R1 N0M0, Gleason score 5-10 prostatic carcinoma. A phase III study.

EORTC trial 26062-22061
A randomized phase III study of Temozolomide and short-course Radiation versus short-course Radiation alone in the treatment of newly diagnosed glioblastoma multiforme in elderly patients

EORTC trial 30071
Double blind randomized phase II Trial in patients with advanced urothelial tract cancer (T3b,T4/N+/M+) of Gemcitabine and Cisplatin with Sorafenib or placebo.

EORTC trial 30072
A Phase III Randomised Double-blind Study Comparing Sorafenib With Placebo In Patients With Resected Primary Renal Cell Carcinoma at High or Intermediate Risk of Relapse

EORTC trial 62063
A phase III randomized study evaluating surgery of residual disease in patients with metastatic gastro-intestinal stromal tumor responding to Imatinib mesylate

Back to news list

Related News

  • EORTC Quality of Life Group celebrating 40 years

  • Results of two EORTC studies have been published in NEJM and the Lancet Oncology

  • Interview with Winette van der Graaf: enhanced patient participation in trials may help make cancer research more heterogeneous

  • New results, updates, and forthcoming EORTC trials in melanoma, soft tissue sarcoma, head and neck, testicular and lung cancer presented at ESMO 2022

  • Important new data from EORTC trials to be presented at ESMO 2022

  • EORTC Item Library provides considerable coverage of CTCAE side effects, new study finds

  • EORTC Completes Patient Recruitment to Study of Treatment for unresectable or metastatic melanoma

  • In Memoriam: Dr Martin Charles Mihm

  • The 1500th patient has been enrolled in the E²-RADIatE cohort OLIGOCARE (RP-1822)

  • PRESS RELEASE: Better treatment for better health: lifting the veil on treatment optimisation